Rompag Eltrombopag 50mg tablets are used to treat low platelet counts caused by chronic immune thrombocytopenic purpura (ITP), chronic hepatitis C virus (HCV) infection, or severe aplastic anemia.
Rompag (Eltrombopag) 50mg tablet is a thrombopoietin receptor agonist that stimulates the production of new platelets in the blood, which helps reduce bleeding. Take this medication exactly as prescribed by your doctor. You should swallow it whole, without chewing, crushing, or breaking it, on an empty stomach. Be sure to tell your doctor about any drug allergies before starting treatment.
Before taking this medicine, inform your doctor about any pre-existing medical conditions. Also, share details of all other medications you are currently using, as interactions may occur. If you have liver disease, dose adjustments may be necessary, so make sure to discuss this with your doctor.
Uses of Eltrombopag tablet
1. Chronic idiopathic thrombocytopenia
2. ITP or HCV infection causes a low platelet count.
3. Treatment of Severe Aplastic Anemia
Benefits of Eltrombopag tablet
ITP or HCV infection causes a low platelet count.
Rompag 50mg tablets is used to increase platelet count in adults and children aged 1 year and older with chronic idiopathic thrombocytopenic purpura (ITP), a condition that causes low platelet levels, leading to unusual bruising or bleeding. Patients who have not responded to or are unable to tolerate other treatments, such as medications or spleen removal surgery, receive a prescription for this tablet. Additionally, Revolade 50mg Tablet is used to boost platelet levels in individuals with hepatitis C, a viral infection that can damage the liver. Typically, doctors combine it with other medications.
In the treatment of severe aplastic anemia
Rompag 50mg Tablet is also used in combination with other medications to treat aplastic anemia, a condition where the body fails to produce enough new blood cells, in adults and children aged 2 years and older. Take this medication exactly as prescribed by your doctor to achieve the best results.
How to use Eltrombopag tablet
Take this medication exactly as prescribed by your doctor, in the recommended dose and duration. Swallow the tablet whole without chewing, crushing, or breaking it. Rompag 50mg tablet should be taken on an empty stomach.
How Eltrombopag tablet works
Rompag Eltrombopag 50mg Tablet is a thrombopoietin receptor agonist that stimulates the production of new platelets in the blood, which helps reduce or prevent bleeding.
Therapeutic Effects of Rompag Eltrombopag 50mg tablet
Rompag Eltrombopag 50mg tablets stimulate megakaryocytes (the large bone marrow cells) responsible for producing platelets. By raising the number of platelets in the blood, this drug prevents bleeding and bruising.
Drug Interactions with Rompag 50mg Tablet
Inform your healthcare provider about all the medications you are taking, including prescription drugs, over-the-counter medicines, nutritional or vitamin supplements, and herbal products. Certain medications, such as antacids, statins, ciclosporin, methotrexate, topotecan, lopinavir, and ritonavir, and vitamin or mineral supplements, may interact with Rompag 50mg Tablet. These interactions could reduce its effectiveness or cause unwanted side effects.
Fact Box of Rompag 50mg tablet
Molecule name: Eltrombopag
Therapeutic class: Anticoagulant
Pharmacological class: Thrombopoietin (TPO) receptor agonist
Indications:
1. Low platelet counts caused by immune primary thrombocytopenia (ITP) or hepatitis C virus (HCV) infection.
2. severe aplastic anemia.
Immune thrombocytopenia (ITP) is a rare blood disorder characterized by a low platelet count. This deficiency in platelets can lead to bruising and excessive bleeding.
2Who should not use the Rompag 50mg Tablet?
People with immune (primary thrombocytopenia (ITP)) and children under one should not use Rompag 50mg tablets. Additionally, individuals with severe aplastic anemia and hepatitis C should not use it.
3Will you be monitored during treatment with the Rompag 50mg Tablet?
Yes, you will be closely monitored while taking Rompag 50mg tablets. Your healthcare provider will routinely assess your white blood cell count, platelet levels, blood clotting factors, heart rate, vision, and perform a complete blood count (CBC).
4Is it safe to take Rompag 50mg tablets on an empty stomach?
Yes, Rompag 50mg tablets should be taken on an empty stomach. This is because antacids, mineral and vitamin supplements (such as iron, calcium, magnesium, aluminum, selenium, and zinc), dairy products, calcium-enriched foods, and fortified juices can interfere with the absorption of the medication. It is recommended to take these substances at least two hours before or four hours after taking Rompag 50mg tablets.
5What are the consequences of discontinuing Rompag 50mg tablets?
Discontinuing Rompag 50mg tablets may lead to a decrease in platelet levels, potentially increasing the risk of bleeding or bruising. It is important to consult your healthcare provider before stopping the medication, as they can provide guidance and monitor your condition to prevent complications.
6Eltrombopag
Eltrombopag
Eltrombopag is used to treat thrombocytopenia (low platelets in the blood) in patients with a blood disorder called chronic immune thrombocytopenia (ITP).
7Eltrombopag olamine
Eltrombopag olamine
Eltrombopag olamine, commonly sold under the brand name Promacta, is a medication used to treat thrombocytopenia, or low platelet levels. It is a thrombopoietin receptor agonist that stimulates the bone marrow to produce more platelets by binding to the thrombopoietin receptor.
8Eltrombopag 25 mg price in india
Eltrombopag 25 mg price in india
INR 970 per strip of 7 tablets
9Eltrombopag cost
Eltrombopag cost
INR 1100 per strip of 7 tablets
10Eltrombopag mechanism of action
Eltrombopag mechanism of action
Eltrombopag is a thrombopoietin receptor agonist that stimulates platelet production. Its mechanism of action involves binding to the thrombopoietin receptor (TPO-R), also known as c-Mpl, which is found on the surface of megakaryocyte progenitor cells in the bone marrow. This binding activates intracellular signaling pathways, including the JAK-STAT and MAPK pathways, promoting the proliferation, differentiation, and maturation of megakaryocytes, which in turn leads to increased platelet production.
Unlike endogenous thrombopoietin, eltrombopag binds to a different site on the TPO receptor, ensuring it does not compete with natural thrombopoietin while still mimicking its effects. This makes it effective in conditions such as immune thrombocytopenia (ITP), chronic hepatitis C-associated thrombocytopenia, and severe aplastic anemia.
